tirzepatide
tirzepatide: sourced relationships with 1 company · 61 clinical trials tracked · 1 FDA decision.
tirzepatide evidence translation
What we can confirm
1 FDA record · 61 tracked trials
What it means
What to watch
Prepared research question
How could tirzepatide → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Reported 2022-05-13 · Current development: unknownSource for the treatment of adults with type 2 diabetes in combinat… | Approved |
| ELI LILLY & Co (LLY) Reported 2022-05-13 · Current development: unknownSource Psoriasis; Type 2 Diabetes; Obesity | Phase 4 |
| ELI LILLY & Co (LLY) Reported 2022-05-13 · Current development: unknownSource for the treatment of adults with type 2 diabetes in combinat… | Approved |
Clinical Trial Registry Records (61)showing 10 most recent
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Primary endpoint: Percentage Change in Body Weight from Baseline to Week 52
An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Tirzepatide to Zenagamtide
Primary endpoint: Number of treatment emergent adverse events (TEAE)
Tirzepatide for Treatment of CCCA
Primary endpoint: Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score
A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity
Primary endpoint: Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Acetaminophen
Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
Primary endpoint: Percent Change from Baseline in Body Mass Index (BMI)
Efficacy of the Dual GIP - GLP-1 Receptor Agonist Tirzepatide in Patients With an Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)
Primary endpoint: Proportion of patients achieving a decrease of the average daily bowel frequency by 30% at week 12 (Week 16 if applicable)
A Phase IV Placebo-controlled Single Center Trial for Tirzepatide in Idiopathic Intracranial Hypertension Trial (TIIHT)
Primary endpoint: Change in intracranial pressure in Idiopathic Intracranial Hypertension (IIH) patients
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
Primary endpoint: Change from baseline in body weight at 48 weeks
A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer
Primary endpoint: Anti-proliferative effect of Tirzepatide
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity: A Double-Blinded Randomized Controlled Trial
Primary endpoint: Change in 6-Minute Walk Distance
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with tirzepatide?
tirzepatide has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve tirzepatide?
BioSniper tracks 61 clinical trials involving tirzepatide.
What is tirzepatide's latest FDA decision?
The most recent tracked FDA decision for tirzepatide is Approval, dated May 13, 2022.